Establishment of a standardized management model for postoperative anti-osteoporosis medication in patients with brittle fractures
- VernacularTitle:脆性骨折术后规范化抗骨质疏松症药物治疗管理模式建立
- Author:
Hao LIU
1
;
Yinglin YANG
1
;
Le CAI
1
;
Shu LI
1
;
Man ZHU
1
;
Mengli CHEN
1
Author Information
1. Dept. of Pharmacy，Medical Supplies Center，Chinese PLA General Hospital，Beijing 100853，China
- Publication Type:Journal Article
- Keywords:
fragility fracture;
resident pharmacists;
osteoporosis;
pharmaceutical service;
clinical pharmacy;
PDCA
- From:
China Pharmacy
2025;36(15):1926-1930
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the establishment and promotion of a new standardized management model for anti- osteoporosis medication after fragility fracture surgery by resident clinical pharmacists， and provide references for resident pharmacists to carry out clinical pharmaceutical services. METHODS From July 2023 to March 2024，595 post-brittle fracture surgery patients were enrolled. Using the PDCA （plan-do-check-act） cycle，resident clinical pharmacists identified issues and conducted investigations in clinical practice. Through integrating clinical pharmacist intervention services before， during and after treatment， a medication treatment pathway was developed， thereby establishing a standardized management model for anti- osteoporosis treatment following fragility fracture surgery. Leveraging the National Brittle Fracture Big Data Platform （under the National Clinical Research Center for Orthopedics and Sports Rehabilitation）， a dedicated data module was constructed， providing big data support to evaluate the efficacy of this pharmaceutical care model. RESULTS Continuous PDCA cycle driven improvements significantly increased the proportion of osteoporosis diagnosis （from 9% before intervention to 81%） and proportion of drug treatment （from 4% to 75%）.The proportions of bone density and bone metabolism testing also rose markedly，positively impacting long-term patient outcomes. CONCLUSIONS The establishment of a standardized management model for anti- osteoporosis treatment following fragility fracture surgery by resident clinical pharmacists has enhanced clinicians’ diagnostic and therapeutic capabilities for osteoporosis， ensures rational medication use in osteoporosis patients， and demonstrates significant potential for widespread adoption and application.
